Stephanie Harris
Clinical Trials Research Associate
I obtained a BSc (Hons) in Biology from the University of Bath in 2006 and have been a member of Helen McShane's Tuberculosis research group at the Jenner Institute since 2009.
My main role is managing the laboratory side of the tuberculosis clinical trials and SARS-CoV-2 challenge studies; preparing for new trials, processing samples from trial volunteers and carrying out immunological assays to assess the response to candidate vaccines and infections. Current TB trials include investigating the immune response to aerosol BCG and development of controlled human infection models for assessing TB vaccine candidates. SARS-CoV-2 challenge studies are ongoing to establish a working model to test vaccines and therapeutics and to better understand the immune response to SARS-CoV-2 infection.
I also work on exploratory projects within the group and co-supervise students and new starters on getting set up and learning laboratory techniques.
Recent publications
-
Early mucosal responses following a randomised controlled human inhaled infection with attenuated Mycobacterium bovis BCG
Journal article
Marshall JL. et al, (2025), Nature Communications, 16
-
Intravenous BCG vaccination in non-human primates induces superior serum antibody titers with enhanced avidity and opsonizing capacity compared to the intradermal route
Journal article
Peralta Alvarez MP. et al, (2024), Vaccine, 42, 126444 - 126444
-
Evaluation of immune profiles associated with control of mycobacterial growth in systemic lupus erythematosus (SLE) patients.
Journal article
Ongarj J. et al, (2024), Tuberculosis (Edinburgh, Scotland), 148
-
Safety of a controlled human infection model of tuberculosis with aerosolised, live-attenuated Mycobacterium bovis BCG versus intradermal BCG in BCG-naive adults in the UK: a dose-escalation, randomised, controlled, phase 1 trial
Journal article
Satti I. et al, (2024), The Lancet Infectious Diseases, 24, 909 - 921
-
Safety, tolerability, viral kinetics, and immune correlates of protection in healthy, seropositive UK adults inoculated with SARS-CoV-2: a single-centre, open-label, phase 1 controlled human infection study
Journal article
Jackson S. et al, (2024), The Lancet Microbe